CN Patent

CN112174982A — 一种洛普替尼晶型及其制备方法

Assigned to Shanghai Acebright Pharmaceuticals Group Co ltd · Expires 2021-01-05 · 5y expired

What this patent protects

本发明提供了(7S,13R)‑11氟‑7,14‑二甲基‑6,7,13,14‑四氢‑1,15‑乙烯桥吡唑并[4,3‑f][1,4,8,10]‑苯并氧杂三氮杂环十三炔‑4(5H)‑酮的新晶型，另一方面，本发明提供了上述晶型的制备方法。与现有技术相比，本发明制备的晶型稳定性高，引湿性低，制备方法简便，溶解性好，适于后续的制剂研发和工业化生产。

USPTO Abstract

本发明提供了(7S,13R)‑11氟‑7,14‑二甲基‑6,7,13,14‑四氢‑1,15‑乙烯桥吡唑并[4,3‑f][1,4,8,10]‑苯并氧杂三氮杂环十三炔‑4(5H)‑酮的新晶型，另一方面，本发明提供了上述晶型的制备方法。与现有技术相比，本发明制备的晶型稳定性高，引湿性低，制备方法简便，溶解性好，适于后续的制剂研发和工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN112174982A
Jurisdiction
CN
Classification
—
Expires
2021-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Acebright Pharmaceuticals Group Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.